CureVac sues Moderna for patent infringement over COVID-19 vaccines
CureVac Announces Voting Results of Extraordinary General Meeting
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac Announces Voting Results of General Meeting
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
European Patent Office declares CureVac mRNA patent valid
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents